Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

VISEN Pharmaceuticals Receives IND Approval to Initiate Phase 2 Clinical Trial of TransCon ™ CNP in Achondroplasia (ACH) in China

prnasiaJanuary 08, 2021

Tag: VISEN Pharmaceuticals , ACH , TransCon , CNP , Clinical Trial

PharmaSources Customer Service